patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

  • Aim to develop and manufacture the best technology graphite in the world
  • Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Close

Message: Pluristem Announces Effectiveness of the Exclusive License Agreement to Develop

Reply New Message
« Prev Message Back To Forum Go to Threaded View Next Message »
Beosound_2
emit
Rank: [?]
Vice President
Points: [?]
21380
Rating: [?]
Votes: 166 Score: 3.0
  • Currently 3.1/5 Stars.
Your Vote:
Please Log In to Vote
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Pluristem Announces Effectiveness of the Exclusive License Agreement to Develop

posted on Aug 03, 11 02:56PM

Pluristem Announces Effectiveness of the Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension

HAIFA, Israel, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI - News) (TASE:PLTR) today announced that following the consent of the Office of the Chief Scientist of Israel, Pluristem's exclusive out-license agreement signed on June 19, 2011 with United Therapeutics Corporation for the use of Pluristem's PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH) has become effective as of August 2, 2011.''

1 recommendations
Reply New Message
« Prev Message Back To Forum Go to Threaded View Next Message »

New Message

Please login to post a reply

Agoracom TV
Check out Agoracom's daily, fast-paced, newscast on the morning's top Small-Cap newsmakers
Featured News
Get top news releases from the Small-Cap world
Blog
Follow George Tsiolis's Small-Cap and Micro-Cap 2.0 Blog

Mesh With Us On The Web's Top Social Networking Sites

YouTube Facebook Twitter Picasa LinkedIn FriendFeed iTunes

Find Our Content Throughout The Web With Our New Media Partners

RIM AOL Yahoo ReportonBusiness

AGORACOM Quick Tips

Looking for a New Junior Zinc Explorer? ... Learn More!
Click To Watch Today's Show

President's D.D.

5-9-12, Pluristem's PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure.
4-17-12, Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial for the treatment of peripheral artery disease (PAD). read more
Beosound_2
Posted by: emit
On: April 18, 2012
URL: http://www.p...4&Itemid=104

Stock Quote

Open PSTI Stock Quote

Investment Ideas

Like Pluristem Life Systems, Inc.? Then you might also be interested in Star Navigation Systems Group Ltd.

Star Navigation Systems Group Ltd.
  • Developer of the TERRASTARTM in-flight safety monitoring system
  • The first system in the world to feature real-time in-flight data monitoring and diagnostics
  • echnical Partnership Agreement with Astrium, a wholly owned subsidiary of EADS

Hub Leaders

Beosound_2
emit
Generic_tiny
emma
Dsc_0077
EDIGOKIE